These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 7689296)

  • 1. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group.
    Gisselbrecht C; Oksenhendler E; Tirelli U; Lepage E; Gabarre J; Farcet JP; Gastaldi R; Coiffier B; Thyss A; Raphael M
    Am J Med; 1993 Aug; 95(2):188-96. PubMed ID: 7689296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
    Oksenhendler E; Gerard L; Dubreuil ML; Levy Y; Matheron S; Cazals-Hatem D; Chevret S; Clauvel JP
    Leuk Lymphoma; 2000 Sep; 39(1-2):87-95. PubMed ID: 10975387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma.
    Gabarre J; Lepage E; Thyss A; Tubiana R; Bastion Y; Schlaifer D; Sebban C; Ribrag V; Fereres M; Raphael M
    Ann Oncol; 1995 Dec; 6(10):1025-32. PubMed ID: 8750156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.
    Coiffier B; Gisselbrecht C; Herbrecht R; Tilly H; Bosly A; Brousse N
    J Clin Oncol; 1989 Aug; 7(8):1018-26. PubMed ID: 2474057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial.
    Levine AM; Wernz JC; Kaplan L; Rodman N; Cohen P; Metroka C; Bennett JM; Rarick MU; Walsh C; Kahn J
    JAMA; 1991 Jul; 266(1):84-8. PubMed ID: 1710673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
    McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
    Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
    Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
    J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
    Haioun C; Lepage E; Gisselbrecht C; Coiffier B; Bosly A; Tilly H; Morel P; Nouvel C; Herbrecht R; D'Agay MF
    J Clin Oncol; 1994 Dec; 12(12):2543-51. PubMed ID: 7527453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
    Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
    Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT).
    Errante D; Tirelli U; Gastaldi R; Milo D; Nosari AM; Rossi G; Fiorentini G; Carbone A; Vaccher E; Monfardini S
    Cancer; 1994 Jan; 73(2):437-44. PubMed ID: 7507401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive treatment of AIDS-related non-Hodgkin's lymphomas with the MACOP-B protocol.
    Schürmann D; Grünewald T; Weiss R; Jautzke G; Pohle HD; Ruf B
    Eur J Haematol; 1995 Feb; 54(2):73-7. PubMed ID: 7535244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84).
    Colombat P; Guilhot F; Bordesoule D; Renou P; Benz-Lemoine E; Fouillard L; Drouet M; Tanzer J; Lamagnere JP
    Haematologica; 1991; 76(6):479-84. PubMed ID: 1726492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
    Sparano JA; Wiernik PH; Hu X; Sarta C; Schwartz EL; Soeiro R; Henry DH; Mason B; Ratech H; Dutcher JP
    J Clin Oncol; 1996 Nov; 14(11):3026-35. PubMed ID: 8918501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases.
    Straus DJ; Huang J; Testa MA; Levine AM; Kaplan LD
    J Clin Oncol; 1998 Nov; 16(11):3601-6. PubMed ID: 9817281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen.
    Sparano JA; Wiernik PH; Strack M; Leaf A; Becker NH; Sarta C; Carney D; Elkind R; Shah M; Valentine ES
    Leuk Lymphoma; 1994 Jul; 14(3-4):263-71. PubMed ID: 7950915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
    Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential versus alternating chemotherapy for high-grade non-Hodgkin's lymphomas: preliminary results of a phase III multicentre trial.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Bruntsch U; Zeller W; Steinhauer EU; Gropp C; Oehl S; Lötzke E
    Onkologie; 1990 Feb; 13(1):28-32. PubMed ID: 2186321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.